Advertisement

Rheumatology International

, Volume 40, Issue 2, pp 207–216 | Cite as

Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial

  • G. S. R. S. N. K. Naidu
  • Shefali Khanna SharmaEmail author
  • M. B. Adarsh
  • Varun Dhir
  • Anindita Sinha
  • Sahajal Dhooria
  • Sanjay Jain
Clinical Trials
  • 113 Downloads

Abstract

The efficacy and safety of mycophenolate mofetil (MMF) has been studied in patients with systemic sclerosis (SSc)-related interstitial lung disease (ILD) with moderate–severe impairment. There is no study on its use in patients with mildly impaired lung function. The objective of this study is to determine the efficacy and safety of MMF for treating mild SSc-ILD (forced vital capacity (FVC) ≥ 70% predicted). This was a double-blind, randomized, placebo-controlled pilot trial. The subjects with SSc-ILD with FVC ≥ 70% were randomized to receive either MMF (2 g/day) or placebo for 6 months. FVC, diffusing capacity of lungs for carbon monoxide (DLCO), modified Rodnan skin score (mRSS), Short Form-36 (SF36v2), Mahler’s Dyspnoea Index (MDI), and 6-min walk distance (6MWD) were recorded at baseline and at 6 months. Forty-one subjects were included in the study (MMF: 20, placebo: 21). FVC decreased by a median of 2.7% (range − 21 to 9) in MMF arm and increased by 1% (range − 6 to 10) in placebo arm (p = 0.131). SF36v2 scores improved in both the groups. Median change in MDI (3 vs 3), DLCO (1% vs 1.5%), and 6MWD (0 m vs 0 m) was similar between the study groups. MMF was effective in improving mRSS (− 5 vs − 1, p = 0.045) compared to placebo. Adverse events occurred with similar frequency in both the study groups. In this pilot study, MMF did not result in significant improvement in lung function in SSc-ILD with minimally impaired lung function, but was effective in reducing the skin tightness. Larger studies are needed to confirm these findings. This study was registered at ClinicalTrials.gov (NCT02896205).

Keywords

Systemic sclerosis Interstitial lung disease Mycophenolate mofetil Spirometry Quality of life Modified Rodnan skin score 

Notes

Acknowledgements

We would like to thank Ipca Laboratories Limited, Mumbai, India for supplying the study drugs, MMF and placebo free of cost. This study was investigator-initiated and none of the personnel from the drug company was involved in the design, performance, or data analysis of the study or writing or reviewing of the manuscript.

Author contributions

All authors contributed to the design of the study, interpretation of the data, manuscript preparation and critical revisions of the manuscript. All authors approved the final version submitted for publication and agree to be accountable for all aspects of the study. Conception and design of the study: GN, SKS, VD, AS and SD. Data collection: GS, AM and SJ. Statistical analysis and data interpretation: GN, SKS, AM, VD and SD. Manuscript preparation: GN, AM, VD and SD. Manuscript revision: GN, SKS, VD, AS, SD and SJ.

Funding:

No funding was received by any of the authors.

Compliance with ethical standards

Conflict of interest

GSRSNK Naidu, Shefali Khanna Sharma, Adarsh MB, Varun Dhir, Anindita Sinha, Sahajal Dhooria and Sanjay Jain declare that they have no conflict of interest. All the authors declare that they have no relationship with the organization promoting MMF.

Informed consent

A written informed consent was obtained from all the participants included in this study and no identifying information of any participant was included in this article.

Ethical statement

The study was approved by the Institute of Ethics Committee (Ref. No. NK/2612/DM/10772). All the procedures performed in this study were in accordance to the guidelines set up by the Declaration of Helsinki in 1964 and later amended in 2000.

Supplementary material

296_2019_4481_MOESM1_ESM.jpg (66 kb)
Fig. S1 Change in FVC from baseline to 6 months in individual subject in both the study groups. FVC: forced vital capacity; MMF: mycophenolate mofetil. (JPG 66 kb)

References

  1. 1.
    Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A et al (2017) Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 76:1897–1905.  https://doi.org/10.1136/annrheumdis-2017-211448 CrossRefPubMedGoogle Scholar
  2. 2.
    Tyndal AJ, Banert B, Vonk M, Airò P, Cozzi F, Carreira PE et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69:1809–1815.  https://doi.org/10.1136/ard.2009.114264 CrossRefGoogle Scholar
  3. 3.
    Rubio-Rivas M, Royo C, Simeon CP, Corbella X, Fonollosa V (2014) Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum 44:208–219.  https://doi.org/10.1016/j.semarthrit.2014.05.010 CrossRefPubMedGoogle Scholar
  4. 4.
    McNearney TA, Reveille JD, Fischbach M, Friedman AW, Lisse JR, Goel N Tan FK, Zhou X, Ahn C, Feghali-Bostwick CA, Fritzler M, Arnett FC, Mayes MD (2007) Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum 57:318–326. https://doi.org/ 10.1002/art.22532CrossRefGoogle Scholar
  5. 5.
    Dhooria S, Agarwal R, Sehgal IS, Prasad KT, Garg M, Bal A, Aggarwal AN, Behera D (2018) Spectrum of interstitial lung diseases at a tertiary center in a developing country: a study of 803 subjects. PLoS ONE 13:e0191938.  https://doi.org/10.1371/journal.pone.0191938 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655–2666.  https://doi.org/10.1056/NEJMoa.055120 CrossRefPubMedGoogle Scholar
  7. 7.
    Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54:3962–3970.  https://doi.org/10.1002/art.22204 CrossRefPubMedGoogle Scholar
  8. 8.
    Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomized controlled, double blind, parallel group trial. Lancet Respir Med 4:708–719.  https://doi.org/10.1016/S2213-2600(16)30152-7 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Omair MA, Alahmadi A, Johnson SR (2015) Safety and effectiveness of Mycophenolate in systemic sclerosis. A systematic review. PLoS One 10:e0124205.  https://doi.org/10.1371/journal.pone.0124205 CrossRefPubMedGoogle Scholar
  10. 10.
    Allison AC (2005) Mechanisms of action of mycophenolate mofetil. Lupus 14(Suppl 1):s2–8CrossRefGoogle Scholar
  11. 11.
    Iudici M, Moroncini G, Cipriani P, Giacomelli R, Gabrielli A, Valentini G (2015) Where are we going in the management of interstitial lung disease in patients with systemic sclerosis? Autoimmu Rev 14:575–578.  https://doi.org/10.1016/j.autrev.2015.02.002 CrossRefGoogle Scholar
  12. 12.
    Guler SA, Winstone TA, Murphy D, Hague C, Soon J, Sulaiman N, Li KH, Dunne J, Wilcox PG, Ryerson CJ (2018) Does systemic sclerosis-associated interstitial lung disease burn out? Specific phenotypes of disease progression. Ann Am Thorac Soc 15:1427–1433.  https://doi.org/10.1513/AnnalsATS.201806-362OC CrossRefPubMedGoogle Scholar
  13. 13.
    Kolb M, Richeldi L, Behr J, Maher TM, Tang W, Stowasser S, Hallmann C, du Bois RM (2017) Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax 72:340–346.  https://doi.org/10.1136/thoraxjnl-2016-208710 CrossRefPubMedGoogle Scholar
  14. 14.
    van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis 72:1747–1755.  https://doi.org/10.1136/annrheumdis-2013-204424 CrossRefPubMedGoogle Scholar
  15. 15.
    Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, Macintyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J, ATS/ERS Task Force (2005) Standardisation of spirometry. Eur Respir J 26:319–338.  https://doi.org/10.1183/09031936.05.00034805 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CPM, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J, Jensen R, McKay R, Miller MR, Navajas D, Pederson OF, Pellegrino R, Wanger J (2005) Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 26:720–735.  https://doi.org/10.1183/09031936.05.00034905 CrossRefPubMedGoogle Scholar
  17. 17.
    Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, Silman AJ, Allegar N, Varga J, Massa M (1993) Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 20:1892–1896PubMedGoogle Scholar
  18. 18.
    Mahler DA, Weinberg DH, Wells CK, Feinstein AR (1984) The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 85:751–758.  https://doi.org/10.1378/chest.85.6.751 CrossRefPubMedGoogle Scholar
  19. 19.
    Shenoy PD, Bavaliya M, Sashidharan S, Nalianda K, Sreenath S (2016) Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis. Arthritis Res Ther 18:123.  https://doi.org/10.1186/s13075-016-1015-0 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Baqir M, Makol A, Osborn TG, Bartholmai BJ, Ryu JH (2017) Mycophenolate mofetil for scleroderma-related interstitial lung disease: a real world experience. PLoS ONE 12:e0177107.  https://doi.org/10.1371/journal.pone.0177107 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Liossis SNC, Bounas A, Andonopoulos AP (2006) Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) 45:1005–1008.  https://doi.org/10.1093/rheumatology/kei211 CrossRefGoogle Scholar
  22. 22.
    Zamora AC, Wolters PJ, Collard HR, Connolly MK, Elicker BM, Webb WR, King TE Jr, Golden JA (2008) Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Resp Med 102:150–155.  https://doi.org/10.1016/j.rmed.2007.07.021 CrossRefGoogle Scholar
  23. 23.
    Gerbino AJ, Goss CH, Molitor JA (2008) Effect of mycophenolate mofetil on pulmonary function in scleroderma- associated interstitial lung disease. Chest 133:455–460.  https://doi.org/10.1378/chest.06-2861 CrossRefPubMedGoogle Scholar
  24. 24.
    Melissaropoulos K, Kraniotis P, Bogdanos D, Dimitroulas T, Sakkas L, Daoussis D (2019) Targeting very early systemic sclerosis: a case-based review. Rheumatol Int 39:1961–1970.  https://doi.org/10.1007/s00296-019-04357-x CrossRefPubMedGoogle Scholar
  25. 25.
    Herrick AL, Pan X, Peytrignet S, Lunt M, Hesselstrand R, Mouthon L et al (2017) Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis 76:1207–1218.  https://doi.org/10.1136/annrheumdis-2016-210503 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Boonstra M, Meijs J, Dorjee AL, Marsan NA, Schouffoer A, Ninaber MK, Quint KD, Bonte-Mineur F, Huizinga TWJ, Scherer HU, de Vries-Bouwstra JK (2017) Rituximab in early systemic sclerosis. RMD Open 3:e000384.  https://doi.org/10.1136/rmdopen-2016-000384 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Sakkas LI, Simopoulou T, Katsiari C, Bogdanos D, Chikanza IC (2015) Early systemic sclerosis- opportunities for treatment. Clin Rheumatol 34:1327–1331.  https://doi.org/10.1007/s10067-015-2902-5 CrossRefPubMedGoogle Scholar
  28. 28.
    Maruish ME (2011) User’s manual for the SF-36v2 Health Survey, 3rd edn. Quality Metric Incorporated, Lincoln, RIGoogle Scholar
  29. 29.
    Chan PT, Mok CC, Chan KL, Ho LY (2014) Functioning and health-related quality of life in Chinese patients with systemic sclerosis: a case control study. Clin Rheumatol 33:659–666.  https://doi.org/10.1007/s10067-014-2525-2 CrossRefPubMedGoogle Scholar
  30. 30.
    Derk CT, Grace E, Shenin M, Naik M, Schulz S, Xiong W (2009) A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology (Oxford) 48:1595–1599.  https://doi.org/10.1093/rheumoatology/kep295 CrossRefGoogle Scholar
  31. 31.
    Khanna D, Tseng CH, Furst DE, Clements PJ, Elashoff R, Roth M, Elashoff D, Tashkin DP (2009) Minimally important differences in the Mahler’s transition dyspnoea index in a large randomized controlled trial- results from the scleroderma lung study. Rheumatology (Oxford) 48:1537–1540.  https://doi.org/10.1093/rheumatology/kep284 CrossRefGoogle Scholar
  32. 32.
    Le EN, Wigley FM, Shah AA, Boin F, Hummers LK (2011) Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 70:1104–1107.  https://doi.org/10.1136/ard.2010.142000 CrossRefPubMedGoogle Scholar
  33. 33.
    Khanna D, Clements PJ, Volkmann ER, Wilhalme H, Tseng CH, Furst DE, Roth MD, Distler O, Tashkin DP (2019) Minimal clinically important differences for the modified Rodnan skin score: results from the scleroderma lung studies (SLS-I and SLS-II). Arthritis Res Ther 21:23.  https://doi.org/10.1186/s13075-019-1809-y CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Mendoza FA, Nagle SJ, Lee JB, Jimenez SA (2012) A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol 39:1241–1247.  https://doi.org/10.3899/jrheum.111229 CrossRefPubMedGoogle Scholar
  35. 35.
    Dhooria S, Agarwal R, Gupta D (2015) Is pirfenidone ready for use in non-idiopathic pulmonary fibrosis interstitial lung diseases? Lung India 32:4–5.  https://doi.org/10.4103/0970-2113.148369 CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Udwadia ZF, Mullerpattan JB, Balakrishnan C, Richeldi L (2015) Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis. Lung India 32:50–52.  https://doi.org/10.4103/0970-2113.148451 CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Khanna D, Albera C, Fischer A, Khalidi A, Raghu G, Chung L, Chen D, Schiopu E, Tagliaferri M, Seibold JR, Gorina A (2016) An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS Trial. J Rheumatol 43:1672–1679.  https://doi.org/10.3899/jrheum.151322 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Internal MedicinePost Graduate Institute of Medical Education and Research (PGIMER)ChandigarhIndia
  2. 2.Department of Pulmonary MedicinePost Graduate Institute of Medical Education and Research (PGIMER)ChandigarhIndia
  3. 3.Department of Radiodiagnosis and ImagingPost Graduate Institute of Medical Education and Research (PGIMER)ChandigarhIndia

Personalised recommendations